title: EGFR and Her2/neu immunoexpression in papillary urothelial bladder carcinomas.
abstract: The study analyzes the immunoexpression of EGFR and Her2/neu in 45 cases of papillary urothelial bladder carcinoma. The cases have been investigated through histopathological and immunohistochemistry techniques, the quantification of results considering the number of marked cells and intensity of the reactions. Immunoexpression of EGFR has been observed in 53.3% of cases, the reaction score having high values in moderate carcinomas and poorly differentiated carcinomas with invasion in the muscularis propria or in the entire wall. Immunostain of Her2/neu has been positive in 42.2% of cases, the poorly differentiated carcinomas presenting high scores regardless of tumor stage. The analyzed markers proved useful for identifying urothelial papillary carcinomas with a poorly differentiated grade, which are in an advanced stage.
authors.affiliation: University of Medicine and Pharmacy of Craiova, Romania.
authors.forename: M
authors.initials: M
authors.lastname: Enache
authors.forename: Cristiana Eugenia
authors.initials: CE
authors.lastname: Simionescu
authors.forename: A
authors.initials: A
authors.lastname: Stepan
mesh_terms: D002291:Carcinoma, Papillary / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D066246:ErbB Receptors / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D018773:Genes, erbB-1; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology
chemical_list: D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human